LEADER 03451nam 2200469 450 001 9910640386603321 005 20230509123101.0 010 $a9783031189036$b(electronic bk.) 010 $z9783031189029 024 7 $a10.1007/978-3-031-18903-6 035 $a(MiAaPQ)EBC7169094 035 $a(Au-PeEL)EBL7169094 035 $a(OCoLC)1357017136 035 $a(DE-He213)978-3-031-18903-6 035 $a(PPN)267811926 035 $a(EXLCZ)9925945659300041 100 $a20230509d2023 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aChallenges and opportunities of mRNA vaccines against SARS-CoV-2 $ea multidisciplinary perspective /$fSiguna Mueller 205 $a1st ed. 2023. 210 1$aCham, Switzerland :$cSpringer,$d[2023] 210 4$dİ2023 215 $a1 online resource (460 pages) 311 08$aPrint version: Mueller, Siguna Challenges and Opportunities of MRNA Vaccines Against SARS-CoV-2 Cham : Springer International Publishing AG,c2023 9783031189029 327 $aChapter 1: Introduction -- Part I: Scientifi Underpinnings, early expectations, and emerging challenges from the global inoculation experience -- Chapter 2: Appraisal of Some of the Key Postulates Underlying mRNA Vaccines -- Chapter 3: Relevance for mRNA vaccine safety -- Chapter 4: From Challenges to Opportunities and Open Questions -- Chapter 5: The challenge of evaluating vaccine safety and effectiveness -- Chapter 6: Safeguarding against the analog of antimicrobial-resistance development -- Chapter 7: Scales, pseudoscales, the human factor, and a way forward -- Part II: A deeper dive into mRNA vaccine safety and security, and developments until Delta -- Chapter 8: mRNA Vaccine safety and efficacy - official criteria when AEs are caused by the injection -- Chapter 9: mRNA Covid-19 vaccines best reflect effective pharmaceuticals - basic considerations and LNPs -- Chapter 10: mRNA Covid-19 pharmaceuticals and the spike antigen -- Chapter 11: Other facets of SARS-CoV-2 immunity, the risk of immune tolerance and T cell exhaustion -- Part III: The Omicron variants -- Chapter 12: Omicron -- Chapter 13: Conclusion. 330 $aThis book offers an analytical look at the much debated risks and benefits of the newly developed COVID-19 mRNA-vaccines. As such, it is one of the first books to give a comprehensive overview of mRNA vaccines against COVID-19 and the only one that addresses this topic from a broad multidisciplinary background. It brings together insights from various underlying disciplines on the challenges of developing and evaluating the most suitable vaccines for mass vaccination programs enrolled throughout the world - focusing on safety and efficacy. This book should not be missing on the shelf of any biomedical researcher, epidemiologist, public health professional or clinical researcher interested in SARS-CoV2 or virology and vaccine development in general. . 606 $aCOVID-19 (Disease)$xPrevention 606 $aCOVID-19 vaccines 615 0$aCOVID-19 (Disease)$xPrevention. 615 0$aCOVID-19 vaccines. 676 $a362.1962414 700 $aMueller$b Siguna$01354578 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 912 $a9910640386603321 996 $aChallenges and Opportunities of mRNA Vaccines Against SARS-CoV-2$93344795 997 $aUNINA